Table 1.
Baseline characteristics of RED-ROSE cohort versus ROSE cohort
| Characteristic | RED-ROSE (N=232) |
ROSE (N=360) |
|---|---|---|
| Age, years | 69 (62–79) | 70 (62–79) |
| Male sex | 159 (69%) | 264 (73%) |
| White race | 166 (72%) | 272 (76%) |
| HF hospitalization | 143 (62%) | 240 (67%) |
| Ejection fraction, % | 35 (23–54) | 34 (21–53) |
| Ejection fraction ≥ 50% | 76 (33%) | 94 (26%) |
| Hypertension | 195 (84%) | 298 (83%) |
| Diabetes | 127 (55%) | 200 (56%) |
| Stroke | 21 (9%) | 31 (9%) |
| Atrial fibrillation | 135 (58%) | 215 (60%) |
| COPD | 59 (25%) | 95 (26%) |
| Medications | ||
| Loop diuretic | 215 (93%) | 340 (94%) |
| ACE or ARB | 112 (48%) | 179 (50%) |
| Hydralazine | 52 (22%) | 68 (19%) |
| Nitrates | 60 (26%) | 90 (25%) |
| Beta blocker | 196 (84%) | 300 (83%) |
| Aldosterone antagonist | 68 (29%) | 109 (30%) |
| Digoxin | 53 (23%) | 89 (25%) |
| Clinical Examination | ||
| Heart rate (bpm) | 74 (66–85) | 74 (65–85) |
| Systolic BP, mmHg | 116 (104–129) | 114 (103–127) |
| Body mass index, Kg/m2 | 31 (27–37) | 31 (27–37) |
| JVP ≥ 8 cm, | 212 (95%) | 327 (95%) |
| Rales | 122 (54%) | 197 (56%) |
| Edema ≥ 2+/4+ | 159 (69%) | 251 (70%) |
| Orthopnea | 193 (88%) | 307 (90%) |
| Laboratory data | ||
| Hemoglobin, g/dL | 11.5 (10.4–12.8) | 11.4 (10.3–12.7) |
| eGFR, mL/min/1.73m2 | 45 (33–56) | 42 (32–53) |
| NT Pro-BNP, pg/mL | 5055 (2358–10348) | 5323 (2420–10797) |